Je was op zoek naar: albicans (Engels - Deens)

candida albicans
candida albicans

non-albicans speciesd
non-albicans arterd

sailfish: istiophorus albicans
sejlfisk: istiophorus albicans

non-albicans species ¶: all
non-albicans species ¶: alle

c. albicansd non-albicans speciesd
c. albicansd non- albicans arterd

this may be related to candida albicans infection or hypersensitivity.
disse kan være relateret til infektion med candida albicans eller overfølsomhed.

c. albicans) and fungicidal activity against all aspergillus species tested.
c. albicans) og fungicid aktivitet over for alle undersøgte aspergillus arter.

candida albicans: s ≤0.06 mg/l, r >0.06 mg/l
candida albicans: s ≤0,06 mg/l, r >0,06 mg/l

non-albicans species ¶: allc. tropicalis c. parapsilosis c. glabrata c. krusei
non-albicans species ¶: alle c. tropicalis c. parapsilosis c. glabrata c. krusei

the species most frequently involved in causing human infections include c. albicans, c. parapsilosis,
de arter, der oftest forårsager infektioner hos mennesker, omfatter c. albicans, c. parapsilosis,

candida albicans non-albicans species ¶: all c. tropicalis c. parapsilosis c. glabrata c. krusei
candida albicans

1 mics for c. tropicalis are 1-2 two-fold dilution steps higher than for c albicans and c. glabrata.
1 mics for c. tropicalis er 1-2 to-fold fortyndingstrin højere end for c. albicans og c. glabrata.

a ratio of ~2400 and ~1300 was required for c. albicans and c. glabrata, respectively, in these models.
en ratio på ~2400 og ~1300 var nødvendig for henholdsvis c. albicans og c. glabrata i disse modeller.

3 in clinical studies, response to voriconazole in c. krusei infections was similar to c. albicans, c. parapsilosis and c. tropicalis.
3 i kliniske studier svarede responset på voriconazol hos patienter med infektion med c. krusei til responset ved c. albicans, c. parapsilosis og c. tropicalis.

anidulafungin exhibited in-vitro activity against c. albicans, c. glabrata, c. parapsilosis, c. krusei and c. tropicalis.
anidulafungin udviser in vitro-aktivitet over for c. albicans, c. glabrata, c. parapsilosis, c. krusei og c. tropicalis.

2 in clinical studies, response to voriconazole in patients with c glabrata infections was 21% lower compared to c. albicans, c. parapsilosis and c. tropicalis.
2 i kliniske forsøg var responset på voriconazol 21% lavere hos patienter med infektion med c. glabrata sammenlignet med c. albicans, c. parapsilosis og c. tropicalis.

2 in clinical studies, response to voriconazole in patients with c. glabrata infections was 21% lower compared to c. albicans, c. parapsilosis and c. tropicalis.
2 i kliniske studier var responset på voriconazol 21% lavere hos patienter med infektion med c. glabrata sammenlignet med c. albicans, c. parapsilosis og

in vitro, voriconazole displays broad-spectrum antifungal activity with antifungal potency against candida species (including fluconazole -resistant c. krusei and resistant strains of c. glabrata and c. albicans) and fungicidal activity against all aspergillus species tested.
voriconazol udviser bredspektret antimykotisk aktivitet in vitro med antimykotisk styrke over for candida arter (herunder fluconazol resistente c. krusei og resistente stammer af c. glabrata og c. albicans) og fungicid aktivitet over for alle undersøgte aspergillus arter.